Table 4.
Arginine-induced maximal secretion test
| Intervention | PLA+NaCl | PLA+GIP | PLA+GLP-1 | SU+NaCl | SU+GIP | SU+GLP-1 | Interaction P value |
|---|---|---|---|---|---|---|---|
| C-peptide | |||||||
| HNF1A mutation carriers | |||||||
| Peak (nmol/L) | 1.2 ± 0.1 | 1.4 ± 0.2 | 1.8 ± 0.2*‡ | 1.8 ± 0.2 | 2.2 ± 0.3*†‡ | 2.5 ± 0.3*†‡§ | 0.1963 |
| AUC120–125 min (nmol/L × min) | 4.9 ± 0.4 | 5.4 ± 0.7 | 7.0 ± 0.7* | 6.8 ± 0.8 | 9.3 ± 1.1*†‡ | 10.0 ± 1.0*†‡§ | 0.1193 |
| iAUC120–125 min (nmol/L × min) | 2.2 ± 0.3 | 2.1 ± 0.4 | 2.8 ± 0.4 | 3.1 ± 0.4 | 3.2 ± 0.5 | 3.9 ± 0.6‡ | 0.9680 |
| Control subjects without diabetes | |||||||
| Peak (nmol/L) | 2.2 ± 0.2 | 3.0 ± 0.3 | 3.4 ± 0.4* | 2.9 ± 0.4 | 3.7 ± 0.5 | 5.0 ± 0.6*†‡§ | 0.1801 |
| AUC120–125 min (nmol/L × min) | 8.3 ± 0.9 | 12.3 ± 1.1 | 14.1 ± 1.7* | 11.8 ± 1.7 | 16.1 ± 2.1* | 22.0 ± 2.6*†‡§ | 0.1385 |
| iAUC120–125 min (nmol/L × min) | 4.8 ± 0.6 | 5.3 ± 0.7 | 5.7 ± 0.6 | 5.8 ± 0.9 | 5.9 ± 0.9 | 6.9 ± 1.0 | 0.8340 |
| Glucagon | |||||||
| HNF1A mutation carriers | |||||||
| Peak (nmol/L) | 41 ± 5 | 44 ± 4 | 36 ± 4 | 32 ± 4 | 35 ± 3 | 34 ± 4 | 0.1797 |
| AUC120–125 min (nmol/L × min) | 508 ± 71 | 428 ± 88 | 293 ± 52 | 414 ± 69 | 467 ± 89 | 356 ± 55 | 0.2300 |
| iAUC120–125 min (nmol/L × min) | 128 ± 16 | 129 ± 13 | 104 ± 15 | 95 ± 17 | 112 ± 11 | 109 ± 17 | 0.2671 |
| Control subjects without diabetes | |||||||
| Peak (nmol/L) | 30 ± 4 | 31 ± 3 | 25 ± 3 | 24 ± 3 | 26 ± 3 | 20 ± 3† | 0.9993 |
| AUC120–125 min (nmol/L × min) | 287 ± 50 | 256 ± 41 | 160 ± 39* | 237 ± 41 | 217 ± 32 | 212 ± 54 | 0.2801 |
| iAUC120–125 min (nmol/L × min) | 99 ± 14 | 97 ± 13 | 73 ± 16 | 78 ± 15 | 79 ± 12 | 79 ± 15 | 0.5468 |
Data are mean ± SEM. iAUC120–125 min is the incremental values from time 120 min, when 5 g arginine was given as a bolus.
PLA, placebo.
Symbols show significant differences (P < 0.05) between interventions:
*
significantly greater than PLA+NaCl;
†
significantly greater SU+NaCl;
‡
significantly greater than PLA+GIP;
§
significantly greater than PLA+GLP-1.